Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
9.03
-0.12 (-1.31%)
Feb 21, 2025, 4:00 PM EST - Market closed
Cullinan Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Cullinan Therapeutics stock have an average target of 32.5, with a low estimate of 26 and a high estimate of 40. The average target predicts an increase of 259.91% from the current stock price of 9.03.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cullinan Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $28 → $33 | Strong Buy | Maintains | $28 → $33 | +265.45% | Jan 29, 2025 |
| UBS | UBS | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +232.23% | Oct 24, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +210.08% | Oct 16, 2024 |
| Wedbush | Wedbush | Buy Reiterates $36 | Buy | Reiterates | $36 | +298.67% | Sep 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +210.08% | Sep 17, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
8.56M
EPS This Year
-3.12
from -3.69
EPS Next Year
-3.15
from -3.12
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | 47.3M | 84.0M | |||
| Avg | n/a | 8.6M | 34.0M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | 881.8% | |||
| Avg | - | - | 296.9% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -3.02 | -2.78 | -2.60 | |||
| Avg | -3.12 | -3.15 | -3.06 | |||
| Low | -3.07 | -4.07 | -4.66 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.